-
EP3759221
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3759221
| EP3759221 - INHIBITION OF POLYOMAVIRUS REPLICATION [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 29.12.2023 Database last updated on 12.11.2024 | |
| Former | Request for examination was made Status updated on 04.12.2020 | ||
| Former | The international publication has been made Status updated on 07.09.2019 | ||
| Former | unknown Status updated on 08.05.2019 | Most recent event Tooltip | 04.05.2024 | New entry: Reply to examination report | Applicant(s) | For all designated states Academisch Ziekenhuis Leiden h.o.d.n. LUMC Albinusdreef 2 2333 ZA Leiden / NL | [2021/01] | Inventor(s) | 01 /
VAN DER VEER, Eric Peter c/o Albinusdreef 2 2333 ZA Leiden / NL | 02 /
VAN ZONNEVELD, Anton Jan c/o Albinusdreef 2 2333 ZA Leiden / NL | 03 /
PRINS, Jurriën c/o Albinusdreef 2 2333 ZA Leiden / NL | [2021/01] | Representative(s) | Nederlandsch Octrooibureau P.O. Box 29720 2502 LS The Hague / NL | [N/P] |
| Former [2021/01] | HGF 1 City Walk Leeds LS11 9DX / GB | Application number, filing date | 19720163.5 | 01.03.2019 | [2021/01] | WO2019NL50131 | Priority number, date | EP20180159797 | 02.03.2018 Original published format: EP 18159797 | [2021/01] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2019168402 | Date: | 06.09.2019 | Language: | EN | [2019/36] | Type: | A1 Application with search report | No.: | EP3759221 | Date: | 06.01.2021 | Language: | EN | The application published by WIPO in one of the EPO official languages on 06.09.2019 takes the place of the publication of the European patent application. | [2021/01] | Search report(s) | International search report - published on: | EP | 06.09.2019 | Classification | IPC: | C12N15/113, A61K48/00, A61K31/7088 | [2021/01] | CPC: |
C12N15/1131 (EP,US);
A61K31/7088 (EP);
A61K31/7125 (US);
A61P31/20 (EP);
C12N2310/11 (EP,US);
C12N2310/315 (EP,US);
C12N2310/321 (US);
C12N2310/346 (EP,US);
C12N2310/3517 (EP);
| C-Set: |
C12N2310/321, C12N2310/3521 (EP);
C12N2310/321, C12N2310/3525 (EP) | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/01] | Title | German: | HEMMUNG DER POLYOMAVIRUSREPLIKATION | [2021/01] | English: | INHIBITION OF POLYOMAVIRUS REPLICATION | [2021/01] | French: | INHIBITION DE LA RÉPLICATION DE POLYOMAVIRUS | [2021/01] | Entry into regional phase | 10.09.2020 | National basic fee paid | 10.09.2020 | Designation fee(s) paid | 10.09.2020 | Examination fee paid | Examination procedure | 10.09.2020 | Examination requested [2021/01] | 10.09.2020 | Date on which the examining division has become responsible | 09.04.2021 | Amendment by applicant (claims and/or description) | 04.01.2024 | Despatch of a communication from the examining division (Time limit: M04) | 02.05.2024 | Reply to a communication from the examining division | Fees paid | Renewal fee | 30.03.2021 | Renewal fee patent year 03 | 27.01.2022 | Renewal fee patent year 04 | 31.01.2023 | Renewal fee patent year 05 | 19.01.2024 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]WO2009100351 (ALNYLAM PHARMACEUTICALS INC [US], et al); | [X]WO2012143427 (SANTARIS PHARMA AS [DK], et al); | [A]WO2013119979 (ISIS PHARMACEUTICALS INC [US]); | [AD]WO2015042466 (US HEALTH [US]); | by applicant | WO2012143427 | WO2015042466 |